Cetuximab is a chimeric mouse–human immunoglobulin G1 monoclonal antibody against the epidermal growth factor receptor (EGFR) approved alongside chemotherapy, for KRAS wild-type colorectal cancer treatment, as well as for metastatic or loco-regionally advanced squamous-cell carcinoma of the head and neck8,11–14. The gene discussed is EGFR; the disease is colorectal cancer.